• Media Centre
  • Investor relations
  • Client area
  • Client area
  • Stewardship policy
  • Annual reports service

Form of Proxy

BIOMERIEUX

Notes

No. Proposition For Against Abstain
1

Approval of the parent company financial statements for the year ended December 31, 2025; approval of the total amount of expenses and costs referred to in Article 39-4 of the French Tax Code

2

Approval of the consolidated financial statements for the year ended December 31, 2025

3

Granting of discharge to the directors

4

Appropriation of net income for the year ended December 31, 2025

5

Approval of the related-party agreement relating to the management of employee mobility within entities of the Mrieux Group and the Mrieux Foundation

6

Approval of the related-party sponsorship agreement between the Company and the bioMrieux Endowment Fund

7

Approval of the “We act for the Children” related-party sponsorship agreement between the Company and the bioMrieux Endowment Fund

8

Renewal of the term of office of Alexandre Mrieux as a director

9

Appointment of Franois Lacoste as a director

10

Appointment of Jean-Luc Belingard as a non-voting director (censeur)

11

Determination of the total annual compensation for directors

12

Approval of the compensation policy for corporate officers in accordance with Article L.22-10-8 of the French Commercial Code

13

Approval of the compensation policy for the Chairman of the Board of Directors in accordance with Article L.22-10-8 of the French Commercial Code

14

Approval of the compensation policy for the Chief Executive Officer in accordance with Article L.22-10-8 of the French Commercial Code

15

Approval of the compensation policy for the directors in accordance with Article L.22-10-8 of the French Commercial Code

16

Approval of the information concerning compensation for corporate officers referred to in Article L.22-10-9 I of the French Commercial Code

17

Approval of the fixed, variable and extraordinary elements making up the total compensation and benefits in kind, paid or due to Alexandre Mrieux for 2025

18

Approval of the fixed, variable and extraordinary elements making up the total compensation and benefits in kind, paid or due to Pierre Boulud for 2025

19

Approval of the amended share purchase plan rules for beneficiaries located in the State of California in the US, as adopted by the Chief Executive Officer

20

Authorization given to the Board of Directors to enable the Company to buy back its own shares

21

Authorization given to the Board of Directors to reduce the Company’s share capital by canceling treasury shares

22

Authorization to be given to the Board of Directors to carry out a capital increase reserved for employees participating in a company savings plan

23

Cancellation of shareholders’ pre-emptive subscription rights in favor of employees participating in a company savings plan

24

Authorization to be given to the Board of Directors to grant share subscription or purchase options, without pre-emptive subscription rights

25

Overall limit on authorizations to issue shares

26

Amendments to the Company's articles of association

27

Full powers granted to the bearer of an original copy of the minutes of this Meeting for the purpose of completing formalities